Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) was upgraded by investment analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Tuesday, Zacks reports.
A number of other brokerages also recently issued reports on GYRE. Wall Street Zen raised Gyre Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gyre Therapeutics in a research note on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.
Get Our Latest Research Report on GYRE
Gyre Therapeutics Trading Down 4.8%
Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.19. The firm had revenue of $32.93 million for the quarter, compared to analysts’ expectations of $28.40 million. Gyre Therapeutics had a negative net margin of 14.80% and a negative return on equity of 7.39%. Equities analysts predict that Gyre Therapeutics will post -0.34 EPS for the current fiscal year.
Institutional Trading of Gyre Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. SBI Securities Co. Ltd. increased its position in Gyre Therapeutics by 1.8% during the third quarter. SBI Securities Co. Ltd. now owns 169,717 shares of the company’s stock worth $1,244,000 after buying an additional 2,967 shares in the last quarter. Bank of America Corp DE acquired a new position in Gyre Therapeutics during the second quarter valued at approximately $83,000. BlackRock Inc. acquired a new position in shares of Gyre Therapeutics during the second quarter worth about $6,550,000. Deutsche Bank AG acquired a new stake in Gyre Therapeutics during the 2nd quarter valued at $118,000. Finally, Bank of New York Mellon Corp acquired a new stake in Gyre Therapeutics during the 2nd quarter valued at approximately $414,000. Institutional investors and hedge funds own 23.99% of the company’s stock.
About Gyre Therapeutics
Gyre Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals. Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure.
Read More
- Five stocks we like better than Gyre Therapeutics
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
